Stock Market News4 weeks Amgen Set to Report Q4 Earnings: Is a Beat in the Cards? Zacks
Volume growth of AMGN’s key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
XVolume growth of AMGN’s key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
X